866-997-4948(US-Canada Toll Free)

Refractory Multiple Myeloma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 211 Pages


Global Markets Directs, \'Refractory Multiple Myeloma - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma. 

Refractory Multiple Myeloma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Refractory Multiple Myeloma.
  • A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Refractory Multiple Myeloma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Refractory Multiple Myeloma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Refractory Multiple Myeloma 9
Refractory Multiple Myeloma Therapeutics under Development by Companies 11
Refractory Multiple Myeloma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Refractory Multiple Myeloma Therapeutics - Products under Development by Companies 20
Refractory Multiple Myeloma Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Refractory Multiple Myeloma Therapeutics Development 24
Bristol-Myers Squibb Company 24
Johnson & Johnson 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
Genentech, Inc. 28
Merck & Co., Inc. 29
Millennium Pharmaceuticals, Inc. 30
Novartis AG 31
ImmunoGen, Inc. 32
Pfizer Inc. 33
Teva Pharmaceutical Industries Limited 34
Exelixis, Inc. 35
Celgene Corporation 36
Onyx Pharmaceuticals, Inc. 37
Incyte Corporation 38
AEterna Zentaris Inc. 39
Array BioPharma Inc. 40
Threshold Pharmaceuticals, Inc. 41
Synta Pharmaceuticals Corp. 42
Acceleron Pharma, Inc. 43
Acetylon Pharmaceuticals, Inc. 44
PharmaMar, S.A. 45
Cylene Pharmaceuticals, Inc. 46
Refractory Multiple Myeloma - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
bendamustine hydrochloride - Drug Profile 53
lorvotuzumab mertansine - Drug Profile 55
noscapine - Drug Profile 58
BMS-833923 - Drug Profile 60
panobinostat - Drug Profile 61
dalantercept - Drug Profile 64
carfilzomib - Drug Profile 66
carfilzomib - Drug Profile 69
cabozantinib - Drug Profile 72
mapatumumab - Drug Profile 74
ganetespib - Drug Profile 76
ruxolitinib - Drug Profile 79
ARRY-520 - Drug Profile 83
TH-302 - Drug Profile 85
BMS-936564 - Drug Profile 87
plitidepsin - Drug Profile 88
obatoclax mesylate + [bortezomib] - Drug Profile 89
CX-4945 Oral Formulation - Drug Profile 90
vorinostat + [dexamethasone] + [lenalidomide] - Drug Profile 92
mapatumumab + [bortezomib] - Drug Profile 94
PD-0332991 + [bortezomib] + [dexamethasone acetate] - Drug Profile 96
plitidepsin + [dexamethasone acetate] - Drug Profile 98
dasatinib + lenalidomide + dexamethasone - Drug Profile 99
perifosine + [dexamethasone acetate] - Drug Profile 101
siltuximab + [bortezomib] - Drug Profile 102
lenalidomide - Drug Profile 104
pomalidomide + [dexamethasone acetate] - Drug Profile 107
pomalidomide - Drug Profile 109
pomalidomide - Drug Profile 112
perifosine + [dexamethasone acetate] + [lenalidomide] - Drug Profile 115
tipifarnib + [bortezomib] - Drug Profile 117
AUY-922 + [bortezomib] - Drug Profile 118
Dexamethasone + CC-4047 - Drug Profile 119
bendamustine hydrochloride + [bortezomib] + [dexamethasone acetate] - Drug Profile 120
lorvotuzumab mertansine + [dexamethasone acetate] + [lenalidomide] - Drug Profile 122
Decadron + Biaxin + CC-4047 - Drug Profile 124
dexamethasone + [bortezomib] - Drug Profile 125
bendamustine hydrochloride + [bortezomib] + [dexamethasone acetate] - Drug Profile 126
ixazomib citrate + [dexamethasone acetate] + [lenalidomide] - Drug Profile 127
RG-7444 - Drug Profile 129
bendamustine hydrochloride+ [bortezomib] - Drug Profile 130
TH-302 + [bortezomib] - Drug Profile 131
CEP-18770 + Lenalidomide + Dexamethasone - Drug Profile 132
BMS-936564 + [dexamethasone]+ [lenalidomide] - Drug Profile 133
BMS-936564 + [bortezomib] + [dexamethasone] - Drug Profile 135
tabalumab + [bortezomib] - Drug Profile 136
DFRF-4539A - Drug Profile 137
LGH-447 - Drug Profile 138
pomalidomide + [bortezomib] + [dexamethasone acetate] - Drug Profile 139
yttrium Y 90 Anti-cd45 Monoclonal Antibody Bc8 + [cyclosporine] + [fludarabine phosphate] + [mycophenolate mofetil] + Allogeneic Hematopoietic Stem Cell Transplantation + Total-Body Irradiation - Drug Profile 141
TP-1149 - Drug Profile 143
Refractory Multiple Myeloma Therapeutics - Drug Profile Updates 144
Refractory Multiple Myeloma Therapeutics - Discontinued Products 197
Refractory Multiple Myeloma Therapeutics - Dormant Products 198
Refractory Multiple Myeloma - Product Development Milestones 200
Featured News & Press Releases 200

Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 208
Disclaimer 208

List of Table


Number of Products Under Development for Refractory Multiple Myeloma, H1 2013 12
Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Development by Companies, H1 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Bristol-Myers Squibb Company, H1 2013 27
Johnson & Johnson, H1 2013 28
Eli Lilly and Company, H1 2013 29
GlaxoSmithKline plc, H1 2013 30
Genentech, Inc., H1 2013 31
Merck & Co., Inc., H1 2013 32
Millennium Pharmaceuticals, Inc., H1 2013 33
Novartis AG, H1 2013 34
ImmunoGen, Inc., H1 2013 35
Pfizer Inc., H1 2013 36
Teva Pharmaceutical Industries Limited, H1 2013 37
Exelixis, Inc., H1 2013 38
Celgene Corporation, H1 2013 39
Onyx Pharmaceuticals, Inc., H1 2013 40
Incyte Corporation, H1 2013 41
AEterna Zentaris Inc., H1 2013 42
Array BioPharma Inc., H1 2013 43
Threshold Pharmaceuticals, Inc., H1 2013 44
Synta Pharmaceuticals Corp., H1 2013 45
Acceleron Pharma, Inc., H1 2013 46
Acetylon Pharmaceuticals, Inc., H1 2013 47
PharmaMar, S.A., H1 2013 48
Cylene Pharmaceuticals, Inc., H1 2013 49
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Stage and Molecule Type, H1 2013 55
Refractory Multiple Myeloma Therapeutics - Drug Profile Updates 147
Refractory Multiple Myeloma Therapeutics - Discontinued Products 200
Refractory Multiple Myeloma Therapeutics - Dormant Products 201
Refractory Multiple Myeloma Therapeutics - Dormant Products (Contd..1) 202

List of Chart


Number of Products under Development for Refractory Multiple Myeloma, H1 2013 12
Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 50
Assessment by Combination Products, H1 2013 51
Assessment by Route of Administration, H1 2013 52
Assessment by Stage and Route of Administration, H1 2013 53
Assessment by Molecule Type, H1 2013 54
Assessment by Stage and Molecule Type, H1 2013 55

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *